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During pregnancy, immune cells infiltrate the placenta at different stages of fetal develop-
ment. NK cells and macrophages are the most predominant cell types. These immune 
cells play pleiotropic roles, as they control spiral artery remodeling to ensure appropriate 
blood supply and maintain long-term tolerance to a true allograft; yet, they must be 
able to mount appropriate immune defenses to pathogens that may threaten the fetus. 
Whether the same cell type accomplishes all these tasks or if there are dedicated sub-
sets remains controversial. Here, we identify and characterize two distinct subsets of 
myeloid cells that differ in their pro-inflammatory/regulatory capacity. While one subset 
predominantly produces the immune-modulating cytokine IL-10, the second subset has 
superior capacity to secrete pro-inflammatory mediators, such as IL-1β and IL-6. The 
putative regulatory myeloid cells also express high levels of inhibitory receptors and their 
ligands, including programmed cell death 1 (PD1) ligands. Importantly, a large fraction of 
CD8 and CD4 cells in normal term human placenta are PD1 positive, suggesting that the 
PD1/PD1 ligands axis might be critical to maintain tolerance during pregnancy.
Keywords: placenta, antigen-presenting cells, inflammation, tolerance, pregnancy
inTrODUcTiOn
Pregnancy is a unique situation during which a truly hemi-allogeneic tissue is well protected from 
the attack of immune cells that would otherwise have the task of defending “self ” from “foreign.” Still, 
maternal cells must be capable of mounting some protective response against bacteria or pathogens 
that may harm the fetus (1). Therefore, there must be mechanisms in place that tightly regulate the 
immune landscape and compromise tolerance with defense during pregnancy (2).
The placenta is heavily infiltrated from immune cells throughout pregnancy (3, 4). The two most 
prominent cell types in the placenta are NK cells and macrophages, both of which exert distinct and 
cooperative functions. Collectively, they are involved in trophoblast invasion, spiral artery remodeling 
and angiogenesis, removal of apoptotic cells, and protection of the implant from infections (3, 5).
To understand how tolerance is enforced in human placenta, we evaluated dendritic cell (DC) 
representation in this tissue, as DCs are key to maintain peripheral tolerance (6). Surprisingly, we 
found very few DCs in the basal plate (BP) of normal term human placenta. We instead directed our 
attention to a subset of CD14+ MHC classIIhigh myeloid cells, most likely macrophages, that based 
on functional studies and unbiased gene array profiling appear to have tolerogenic and regulatory 
properties.
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MaTerials anD MeThODs
collection of Placental Tissue
This study was carried out in accordance with the recom-
mendations of Washington University School of Medicine IRB 
committee with written informed consent from all subjects. 
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by the 
Institutional Review Board of the Washington University School 
of Medicine, St. Louis, MO, USA. Placentas were obtained 
from singleton, term (37–40  weeks), uncomplicated gestations 
delivered by scheduled cesarean section under conduction of 
anesthesia without labor or delivered vaginally after spontane-
ous labor, with delivery in 6 h. Placentas were kept at 4°C until 
sampling, with an average time between delivery and sampling of 
60 min (range 30–120 min). The placenta was then submitted to 
random sampling of the BP (maternal–fetal interface), according 
to recommended procedure for placental sample collection (7). 
Five to ten en face sections of BP tissue were taken with ~1.5 cm2 
surface area and <0.5  cm thickness, avoiding areas of visible 
infarcts or calcifications.
isolation of cells from the BP, Flow 
cytometry, and cell sorting
Basal plate tissue was finely minced with scissors, digested with 
collagenase D (1  mg/ml, Roche) for 60  min at 37°C in RPMI 
medium with 10% FBS (Hyclone) and pressed through a series of 
strainers to yield single cells. For identification of DC populations, 
single cells were stained with a combination of lineage markers 
(CD3, CD19-PerCP-Cy5.5 eBioscience; CD16, CD56, and CD14-
PerCP-Cy5.5 Biolegend), CD45-AlexaFluor-700 (Biolegend), 
HLA-DR-APC (BD), ILT3-PE-Cy7 (Biolegend), ILT1-PE (eBio-
science), CD303-FITC (Miltenyi), and CD1c-Brilliant Violet 510 
(Biolegend). Cells were acquired on a LSR-Fortessa (BD) and data 
analyzed with the FlowJo software. For FACS sorting experiments 
CD14 cells were pre-enriched by magnetic purification (CD14 
microbeads, Miltenyi), stained with CD14-FITC (Beckman 
Coulter) and HLA-DR-APC (BD), and separated on FACS-AriaII 
(BD). For morphological analysis, CD14+MHCIIhigh and CD14+ 
MHCIIlow cells were immobilized on slides by cytospin and 
stained with a Hema 3 stain set. Additional antibodies used for 
flow cytometry analysis: immunoglobulin-like transcript (ILT) 2, 
CD40, CD54, CD80, CD50, CD89-PE (Beckman Coulter); ILT4-
APC (eBioscience); ILT5-PE (eBioscience); CXCR4-PE (BD); 
CD91-eFluor660 (eBioscience); CD206-Brilliant Violet 421; 
CRACC-PE, CD180-PE, CLEC4A-PE (Biolegend); DQ-FITC 
(eBioscience); CD9-FITC, CD35-FITC (Beckman Coulter); 
IDO-PE (eBioscience); mouse IgG1 Control-PE (eBioscience); 
CLEC4A-PE (Biolegend); CD3-Brilliant Violet 605 (Biolegend); 
PD1-Brilliant Violet 421 (Biolegend); CD4-APC (eBioscience); 
CD8-PerCP-Cy5.5 (Biolegend); CD8-APC (eBioscience); and 
CD4-APC-eFluor-780 (eBioscience).
statistical analysis
Statistics were calculated as indicated in figure legends using the 
Prism7 software.
histology
Formalin-fixed paraffin-embedded tissue blocks used for this 
study were retrieved from the tissue bank of the Department of 
Pathology (ASST-Spedali Civili di Brescia, Brescia, Italy). Tissues 
used for the analysis included normal placental tissue at the first 
(five cases) and third (ten cases) trimester. Four-micron-thick 
tissue sections were used for immunohistochemical staining. 
Primary antibodies included anti-CD14 (1:50, mouse, clone 7, 
Leica); anti-CD163 (1:50, mouse, clone 10D6, Neomarkers); 
and anti-HLA-DP,DQ,DR(1:500, mouse, clone CR3/43, DAKO). 
The reaction was revealed using Novolink Polymer (Leica 
Microsystems) followed by DAB. Microphtalmia-associated 
transcription factor (MITF) (1:50, mouse, clone D5, DAKO) was 
visualized using Mach 4 MR-AP (Biocare Medical), followed by 
Ferangi Blue (Biocare Medical) as chromogen.
gPnMB staining by immunofluorescence
Cells were FACS sorted and immobilized on slides by cytospin. 
They were then dried overnight and fixed for 15 min in metha-
nol at −20°C. After blocking for 1 h at room temperature with 
PBS containing 5% FBS, cells were incubated with biotinylated 
anti-GPNMB (R&D) (1:100) overnight at 4°C, followed by 1:200 
streptavidin-PE (eBioscience) and DRAQ5 1:500 for DNA stain-
ing. Images were obtained at 600X magnification using a Nikon 
E800 confocal microscope. Three different placentas were sorted 
and cells placed by cytospin on two slides per placenta, and 10 
random pictures of each slide were photographed. Intensity of 
positive cells for GPNMB per field was quantified using ImageJ 
software (NIH), by considering the mean gray value within each 
cell, compared to the average background.
Transcriptome analysis and real-time Pcr
For gene expression microarrays, RNA from sorted populations 
(n = 4 HLA-DRhigh replicates and n = 3 HLA-DRlow replicates) 
was prepared using the RNeasy micro kit (Qiagen), following 
manufacturer instructions. Gene array data analysis and ingenuity 
pathway analysis (IPA) were performed as previously described 
(8). The Affymetrix Human Gene (v.1.0) ST array platform was 
used (8). Microarrays have been deposited in GEO under acces-
sion number GSE104224.
RNA isolation, cDNA generation, and quantitative real-
time PCR (qRT-PCR) were done as previously described (9), 
except using a total reaction volume per well of 10 µl. To verify 
amplification of a single product with the appropriate melting 
temperature, dissociation curves were evaluated for all reactions. 
RNA expression levels were normalized to parallel reactions with 
primers specific for GAPDH. The fold increase gene expression 
in experimental relative to control conditions was determined by 
utilizing the 2−ΔΔCt method (10).
Primer list: GPNMB 5′-TAAACCTTGAGTGCCTGCGT, 
3′-TGAAATCGTTTGG CGGCATC; UBD 5′-TCTCTGGTTT 
CTGGCCCCTT, 3′-CGGAACGGACA TGCACACAG; EBI3  
5′-AGAGCACATCATCAAGCCCG, 3′-CAGCTCCCTGACGC 
TTGTAA; CD80 5′-GGGGAAATGTCGCCTCTCTG, 3′-GTGG 
ATTTAGTTTCACAGCTTGC; IDO1 5′-GATGTGGGCTTTG 
CTCTACC, 3′-GCTTCCCATTCTCAATCAGC; MITF: 5′-TGT 
GACTGAACCAACTGGCACTTAC, 3′-TGCTCCGCCTGCTA 
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CTCGTT; S100A12: 5′-CACTGCTGGCTTTTTGCTGT, 3′-AA 
TGCCCCTTCCGAACTGAG; F5: 5′-CACGTGGTTCACTTT 
CACGG, 3′-AATGAAC CAGGCAGAAGGGG;  and GAPDH: 5′-C 
CTGGTATGACAACGAATTT, 3′-AGTGAGGGTCTCTCTCT 
TCC.
Tissue culture for cytokine Quantification
CD14+ HLA-DRhigh and HLA-DRlow cells were plated in identical 
numbers (105 cells/well in duplicate) in 200 µl of complete RPMI 
medium in wells of a 96 flat bottom plate. Cells were immediately 
stimulated with TLR agonists Resiquimod (5 µg/ml; inVivogen); 
LPS (100 ng/ml, Ultrapure LPS K12; inVivogen); PolyIC (50 µg/
ml; Amersham), Pam3CSK4 (50  ng/ml; inVivogen), and CpG 
1826 (6 µg/ml; Qiagen). Supernatants were collected after 18 h 
and cytokines quantified by Cytometric Beads Arrays (Human 
Inflammation, BD).
collection of Term and Pre-Term 
Placentas for gPnMB Quantification
A case–control study was also included, under local Ethical 
approval. Subjects were enrolled and consented in the Women 
and Infant’s Health Specimen Consortium (WHISC). The study 
was conducted within the Washington University Medical School 
and Barnes Jewish Hospital in Saint Louis, MO, USA from 
September 2014 to April 2016. Samples and demographic data 
collection were de-identified. Placenta was obtained, as previ-
ously described in tissue preparation, from singleton gestation 
of normotensive term (≥37–41 weeks) gestations (n = 20), term 
pre-eclampsia (n = 20), and pre-term pre-eclampsia with severe 
features (≤34  weeks) (n  =  16). Pre-eclampsia was diagnosed 
as new onset of hypertension and either proteinuria or end-
organ dysfunction after 20  weeks of gestation in a previously 
normotensive woman (11). Pre-eclampsia with severe features 
was defined by the presence of one or more of the following: 
unrelieved headache, hepatic abnormality, severe blood pressure 
elevation, thrombocytopenia, progressive renal insufficiency, 
and pulmonary edema (11). Women with multi-fetal gestations, 
known medical conditions, including chronic hypertension, 
diabetes mellitus, renal or collagen vascular disease, and fetal 
chromosomal abnormalities, were excluded.
Random samples of tissue from the BP were retrieved from 
delivered placentas, frozen in liquid nitrogen and stored at 
−80°C. RNA was extracted using TRIzol, cDNA prepared from 
0.5 µg of total RNA and qRT-PCR carried out as described earlier.
resUlTs
Dc subsets in Term Placenta are Poorly 
represented compared to Peripheral 
Blood
To investigate the nature and abundance of DCs in the BP of nor-
mal term human placenta compared to peripheral blood, we took 
advantage of our previous staining criteria to identify DC subsets 
in circulating blood (12). After collagenase extraction, we stained 
placenta cells with a mixture of CD45, to identify hematopoietic 
cells, lineage (Lin) markers (CD3, CD19, CD56, CD14, and CD16) 
to exclude T, B, NK, monocytes, and granulocytes, respectively, 
and HLA-DR. Among CD45+, Lin-negative HLA-DR+ cells, 
we distinguished plasmacytoid DCs (pDCs) and myeloid DCs 
(mDCs) based on the expression of ILTs, ILT3 (CD85K, LILRB4) 
and ILT1 (CD85H, LILRA2). In blood, ILT3 single positive pDCs 
homogenously expressed CD303 (BDCA2), while ILT3/ILT1 
double positive cells uniformly expressed CD1c (Figure  1A). 
However, in placenta, DC subsets were less prominent than in 
blood (Figure  1B). Additionally, the frequency of pDCs and 
mDCs among Lin-negative HLA-DR+ cells was significantly lower 
in the BP tissue (pDCs: 35.9–10.1%; mDCs: 29.2–2.7%) than in 
blood (pDCs: 59.6–30.9%; mDCs: 50.5–30.5%) (Figure  1C). 
Frequencies of pDCs and mDCs in placenta were also signifi-
cantly lower when percentages of the respective DC subsets were 
calculated among total CD45+ hematopoietic cells (Figure 1D) 
(placenta: pDCs: 0.075–0.015%; mDCs: 0.072–0.039%; blood: 
pDCs: 0.35–0.07%; mDCs: 0.18–0.08%).
During these experiments, we noticed a population of Lin+ 
cells in placenta, which exhibited high expression of HLA-DR 
and was poorly represented in blood (Figures  1A,B). We rea-
soned that high expression levels of MHC class II might be linked 
to antigen processing and presentation. Therefore, we further 
sought to better characterize this cell subset.
hla-Drhigh cells are a cD14+ Myeloid cell 
subset That Produces higher levels of 
il-10 upon Tlr stimulation than hla-
Drlow cells
In the attempt to identify the nature of HLA-DRhigh cells in 
placenta, we stained each single lineage marker in combination 
with HLA-DR (not shown). HLA-DRhigh cells expressed the line-
age marker CD14 (Figure 2A), indicating that they represent a 
myeloid/monocytic or macrophagic cell subset. HLA-DRhigh cells 
were always less represented than HLA-DRlow cells among CD14+ 
myeloid cells (average 17.1–41% versus 82.9–56.1%) (Figure 2B). 
When we FACS sorted the two subsets to high purity and stained 
them with an equivalent of the classical Wright-Giemsa stain, 
the morphology of the two subsets was surprisingly similar; 
both populations exhibited an indented nucleus and a cytoplasm 
containing many vacuoles, most likely corresponding to lipid 
droplets (Figure 2C).
Next, we tested the ability of these subsets to respond to TLR 
stimulation and to produce cytokines. We found that both subsets 
responded to some extent to TLR2, TLR4, and TLR7 stimulations 
(Figures 2D,E). However, in general, HLA-DRhigh myeloid cells 
produced more IL-10 in response to both LPS and Resiquimod 
(Figure  2D), although statistical significance was only reached 
for LPS stimulation due to donor variation (Figure S1 in 
Supplementary Material). Conversely HLA-DRlow cells produced 
significantly more IL-1β and IL-6 in response to LPS (Figure 2D; 
Figure S1 in Supplementary Material). Both subsets produced 
TNF-α upon TLR4 engagement, and although more donors 
yielded higher TNF-α secretion from the HLA-DRlow subset 
(Figure 2D), statistical significance was not reached (Figure S1 
in Supplementary Material). Neither subset responded vigorously 
to TLR3 or TLR9 stimulation (Figure 2E).
FigUre 1 | Conventional dendritic cell (DC) subsets are poorly represented in basal plate tissue of normal term placentas. (a) Identification of conventional DC 
subsets in blood and (B) basal plate tissue of normal term placenta. DC subsets were identified within the Lineage negative HLA-DR+ population as ILT3+ILT1− 
plasmacytoid DCs (pDCs), which express BDCA2 (CD303), and as ILT3+ILT1+ myeloid DCs (mDCs), which express CD1c. One representative of eight individual 
donors for blood and placenta is shown. (c,D) Percentages of pDCs and mDCs in blood and placenta among lineage negative HLA-DR+ (c) or among total CD45+ 
(D) cells. Significance was calculated by ordinary one-way ANOVA Tukey’s multiple comparison test. *p < 0.05, **p < 0.005, and ***p < 0.0005.
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We conclude that, despite similar morphologies, the two 
subsets of myeloid cells identified here are prepared to respond 
to pathogens in different ways. HLA-DRlow cells might predomi-
nantly recognize Gram negative bacteria that may invade the 
placenta and they will produce an inflammatory environment to 
curb bacteria spreading. HLA-DRhigh cells may recognize not only 
Gram negative bacteria but also ssRNA viruses or, most likely 
during uncomplicated normal term pregnancy, circulating fetal 
RNAs. By producing higher levels of IL-10 and lower levels of 
IL-6 and IL-1β, this cell subset may generate a tolerogenic milieu 
that avoids fetal rejection.
Unbiased gene expression Profile of the 
Placenta Myeloid subsets Further 
corroborates the Tolerogenic Potential  
of hla-Drhigh cells
In an attempt to better define the nature of the two myeloid 
subsets identified, we analyzed their gene expression signatures 
by global gene array profiling. We selected the genes that were 
significantly differentially expressed greater than two-fold 
between subsets (Figure  3A). As a control, we also compared 
expression of these genes with expression in a distant cell type, 
CD56+ NK cells from human peripheral blood. We identified 287 
transcripts that were over-expressed in HLA-DRhigh cells, while 
167 were over-expressed in the HLA-DRlow subset. These genes 
encode several distinct classes of molecules, including secreted 
molecules, pattern recognition receptors (PRRs), transcription 
factors (TFs), cell surface receptors, and proteins involved in 
cell metabolism or in cell signaling (Figure  3B). Interestingly, 
HLA-DRhigh cells expressed elevated levels of many complement 
factors, such as C1QA, C1QB, and C1QC, C2 and C3, and CFB, 
suggesting that the complement pathway may play a pivotal role 
in pregnancy. In addition, they expressed high levels of APOE and 
APOC2 and many metabolic genes involved in lipid handling and 
modification, such as LPL, SCD, PLTP, FABP5, UGCG, NCEH1, 
SGPL1, and LIPA. Moreover, HLA-DRhigh cells expressed EBI3, 
also known as p28, a common subunit to the cytokines IL-27 
and IL-35, both with known tolerogenic properties. The enzyme 
IDO1 was also preferentially expressed on HLA-DRhigh myeloid 
FigUre 2 | CD14+HLA-DRhigh and CD14+HLA-DRlow cells, despite similar morphologies, respond differently to toll-like receptor (TLR) stimulation. (a) Representative 
sorting gate to separate CD14+HLA-DRlow and CD14+HLA-DRhigh cells. (B) Relative percentages of HLA-DRhigh to HLA-DRlow after purification with CD14 microbeads 
(n = 22). ****p < 0.0001. Significance was calculated by unpaired T-test. (c) Cytospin images of the two myeloid cell subsets. (D) Secretion of IL-1β, IL-6, IL-10, 
and TNF-α from HLA-DRlow or HLA-DRhigh cells from different donors (n = 6). A total of 105 cells were either left unstimulated (medium) or stimulated with LPS and 
resiquimod and cultured for 18 h prior to cytokine quantifications in supernatants. Each color represents a different donor and assays were run in duplicates. An 
arbitrary line was drawn to emphasize enhanced IL-1β and IL-6 secretions by HLA-DRlow, while HLA-DRhigh cells from most donors showed boosted IL-10 secretion. 
(e) IL-10 and IL-6 secretions by HLA-DRlow and HLA-DRhigh placental cells in response to different TLR agonists. One representative donor of 2 tested with 
PAM3CSK4, PolyI:C, and CpG1826, in addition to LPS and Resiquimod, is shown. An arbitrary line was drawn to emphasize differential cytokine secretion.
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FigUre 3 | CD14+HLA-DRlow and HLA-DRhigh have unique transcriptional signatures and differentially express cell surface receptors. (a) Volcano plot representing 
transcripts that are significantly and greater than two-fold expressed by HLA-DRlow (n = 3) (red) versus HLA-DRhigh (n = 4) cells (blue). (B) Heatmaps of transcripts 
differentially expressed between HLA-DRlow and HLA-DRhigh cells and categorized as secreted proteins, pattern recognition receptors (PRRs), transcription factors 
(TFs), cell surface receptors, and molecules involved in metabolism and cell signaling. Transcripts in bold blue (higher expression on HLA-DRhigh) or red (higher 
expression in HLA-DRlow) indicate genes, which were subsequently validated by protein expression or RT-PCR. Human peripheral blood NK cells were used as 
comparison, with the rationale that having an innate but distant cell type may maximize our ability to identify genes differentially expressed between the two myeloid 
cell subsets. (c) Ingenuity pathway analysis networks with highest z-score generated from transcripts differentially expressed between HLA-DRhigh (blue) and 
HLA-DRlow (red) cells. (D) Protein expression of costimulatory and antigen presenting molecules and inhibitory receptors of the immunoglobulin-like transcript family 
on HLA-DRhigh (blue histograms) as compared to HLA-DRlow (red histograms) cells. (e) Increased protein expression of CD274, IDO, CRACC, and CD9 on 
HLA-DRhigh cells and increased expression of CD89, CD35, CD93, and CLEC4A on HLA-DRlow cells. Both subsets express CD206 (mannose receptor) ex vivo.
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FigUre 4 | Tissue histology allows identification of MITF+CD14+ cells in human placenta at different stages of gestation. Sections are from first or third trimester normal 
placenta and stained as labeled. CD163+MIFT+ myeloid are found in placental decidua and placental villi (a–D). MIFT+ myeloid cells that co-express CD14 (e–h) and 
HLA-DR (i–n) can be identified. Some of these cells are located within small fibrin deposits in the perivillous space (M) and within the decidua (i–l). A variable level of 
expression of nuclear MIFT+ is also observed in decidual cells at the 1st trimester (i). Magnification 200× (a–n); scale bare 100 μm. Inserts magnification 600×.
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cells. This enzyme as well as a second isoform, IDO2, induces 
cell tolerance by degrading the essential amino acid tryptophan, 
thus limiting proliferation of antigen stimulated T  cells (13). 
Intriguingly, HLA-DRhigh cells also expressed the TF Blimp-1, 
which was shown to promote and sustain the tolerogenic func-
tion of DCs in female mice (14).
Consistent with the trend of HLA-DRhigh cells producing 
higher levels of IL-10 upon Resiquimod stimulation (Figure S1 in 
Supplementary Material), these cells also expressed higher levels 
of TLR7. Conversely, HLA-DRlow cells had higher transcripts for 
genes involved in inflammation, such as the cytokines IL6, IL8, 
and IL1B. PRRs that are involved in recognition of bacterial com-
ponents and inflammasome activation, such as NOD2 and NLRP3 
were also more highly expressed. Noteworthy, only a few genes 
over-expressed on one of the two subsets were also expressed at 
high levels on peripheral blood NK cells [i.e., CRACC (SLAMF7), 
CD62L (SELL), ITGA6, and ICAM3].
Next, we performed IPA on genes with significant differences 
greater than two-fold between HLA-DRhigh and HLA-DRlow cells. 
This analysis indicated that genes enriched in HLA-DRhigh cells 
were linked to LXR/RXR signaling and PPRα/RXRα activation, 
nuclear receptors that mostly bind fatty acids or retinoids and 
control lipid metabolism. In addition, IPA linked genes enriched 
in HLA-DRhigh cells to DC maturation and to the complement 
system. On the other hand, genes enriched in HLA-DRlow cells 
were connected to IL-6 signaling and to LPS/IL-1- mediated 
inhibition of RXR function, which promotes an inflammatory 
phenotype in macrophages (Figure 3C).
To functionally validate our data, we selected a few cell surface 
receptors for which antibodies were available and measured 
expression of these receptors on the two myeloid subsets. As 
shown in Figure  3D, costimulatory molecules such as CD40, 
CD54, CD80, and CD86, in addition to HLA-DQ, were higher in 
HLA-DRhigh cells, in agreement with the DC maturation pathway 
identified by our IPA. In addition, several inhibitory receptors 
of the ILT family, such as ILT2 (LILRB1), ILT3 (LILRB4), and 
ILT4 (LILRB2) had higher expression on HLA-DRhigh, with ILT5 
(LILRB3) being an exception, as it was higher on HLA-DRlow 
cells. CD274 (PDCD1LG2), a ligand for the inhibitory receptor 
programmed cell death 1 (PD1), had also higher expression on 
HLA-DRhigh, as did the enzyme IDO. Expression of IDO with 
a commercially available antibody was relatively low and an 
isotype-matched control was necessary to show a clear shift of 
the populations (Figure  2E). HLA-DRhigh cells also expressed 
higher level of the CD2 family member CRACC (SLAMF7) (15), 
which mediate homotypic interactions and inhibit inflammatory 
cytokines in activated monocytes (16). Moreover, they expressed 
very high levels of CD9, a tetraspanin induced in human cells by 
TGFβ signaling (17), suggesting that HLA-DRhigh cells may reside 
in a TGFβ rich environment or develop under the influence of 
TGFβ (Figure 3E).
In agreement with our gene array data, HLA-DRlow cells 
expressed higher levels of the IgA-specific Fc receptor CD89; the 
CR1 CD35; CD93, a receptor which promotes phagocytosis of 
apoptotic cells and of antibody and complement opsonized par-
ticles; and the lectin CLEC4A, also known as DICR (18), which 
binds carbohydrates, including some that decorate pathogens 
(19) (Figure 3E). Expression of these receptors supports the idea 
that this myeloid subset might be involved in bacterial recogni-
tion and removal of immunoglobulin or complement opsonized 
pathogens. Notably, CD206, the mannose receptor, was expressed 
on both myeloid subsets ex vivo (Figure 3E), suggesting that these 
cells are tissue specific and not blood derived monocytes, which 
ex vivo are CD206 negative (20).
To localize the two cell types by immunohistochemistry, we 
took advantage of our microarray data showing higher expression 
of MITF on the HLA-DRhigh subset. MITF is a TF of the MITF/
TFE family involved in lysosomal biogenesis (21). We examined 
tissue sections from a set of archival placental tissue from the first 
and the third trimesters of gestation. As shown in Figure 4, many 
FigUre 5 | Validation of additional markers on HLA-DRlow and HLA-DRhigh 
cells by RT-PCR and at protein level (a–c). (a) Quantitative RT-PCR analysis 
of the indicated up- and down-regulated genes in CD14+ MHCIIhigh cells 
relative to expression in CD14+ MHCIIlow cells, using GAPDH as a stable 
reference gene. Data are shown as mean ± SE, with symbols indicating 
results from individual placentas. A letter (i.e., a–c) was included within or next 
to the symbol to indicate matching donors. Statistical significance was 
determined by Student’s t-test. *p < 0.05 and **p < 0.005. (B) Representative 
GPNMB protein expression levels by immunofluorescence in CD14+MHCIIhigh 
and MHCIIlow cells. FACS-sorted cells were co-stained for DNA (blue) and 
GPNMB (green) and the signal intensity of GPNMB determined using 
confocal microscopy. (c) Relative GPNMB signal intensity for the two cell 
types (n = 3). Statistical significance was determined by Student’s t-test. 
*p < 0.05. (D) Lower expression of GPNMB in placentas from pre-term 
preeclamptic pregnancies with severe complications. (D) GPNMB expression 
was determined by RT-PCR in basal plate tissue of placentas from women 
who had normal term pregnancy (Nterm, n = 20), pre-eclampsia and term 
delivery (PEterm, n = 20), and pre-eclampsia with severe complications and 
pre-term delivery (PEpre, n = 16). Values were normalized to GAPDH levels. 
Statistical significance was determined by ordinary one-way ANOVA.
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cells, at both time points, and, in both placental decidua and 
villi, stained positive for CD163 and CD14 (Figures 4A–H), two 
markers, which selectively identify myeloid cells of the monocyte/
macrophage lineage. Some of these cells showed a clear nuclear-
associated staining for MITF (Figures  4B,D,F,H, inserts) and 
seemed inter-dispersed among other CD163+ and CD14+ cells 
that stained negative for MITF, suggesting that the two myeloid 
cell types here identified did not have a distinct localization but 
may mingle in the same tissue microenvironment. By double 
staining with a MHC-class II-specific antibody, we found MHC-
class II+MITF+ cells within small fibrin deposits in the perivillar 
space and within the decidua (Figures 4I–N). However, because 
of the broad MHC-Class II expression in human on many cell 
types, we cannot definitively conclude that those cells represent 
our HLA-DRhigh myeloid cells.
To further confirm the differential expression profile of addi-
tional genes for which antibodies were not readily available, we 
performed real-time PCR experiments. Specifically, we aimed 
to validate EBI3, GPNMB, which is a direct downstream target 
of MITF (22, 23), UBD, the antimicrobial protein S100A12 (24), 
and F5. CD80, IDO, and MITF were included as positive controls. 
Indeed, we found that GPNMB, UBD, and EBI3 were expressed 
at significantly higher levels in HLA-DRhigh than in HLA-DRlow 
cells (Figure 5A). We also tested GPNMB expression by immu-
nofluorescent microscopy at the protein level, as this transcript 
was 80-fold more expressed on HLA-DRhigh than on HLA-DRlow. 
HLA-DRhigh showed high expression of GPNM throughout the 
cytoplasm (Figure  5B), and quantification of the fluorescent 
signal by ImageJ analysis in the two populations was statistically 
significant (Figure 5C).
We conclude that a substantial portion of the data generated by 
our unbiased microarray analysis can be validated at the protein 
level and that pathways such as complement, apolipoproteins, 
inhibitory receptors/ligands, and immunoregulatory cytokines/
enzymes are a major signature of HLA-DRhigh myeloid cells in the 
term human placenta from uncomplicated pregnancies.
Decreased gPnMB expression May 
represent a Prognostic Marker for 
Pregnancy-associated Diseases
A precise function for GPNMB (also known as osteoactivin) 
in immune cells has not been reported. However, this protein, 
which is also released as soluble form, is highly expressed by some 
malignancies, including breast cancers and aggressive melano-
mas. Anti-GPNMB antibodies are currently in clinical trials 
for cancer (25, 26). Because of this link between GPNMB and 
cancer (27, 28), we hypothesized that GPNMB could be involved 
in maintaining a tolerant environment, which promotes a suc-
cessful normal term pregnancy. We therefore sought to quantify 
GPNMB expression by real-time PCR in term placentas without 
pregnancy complications, placentas from term pregnancies 
complicated with pre-eclampsia and placentas from pregnancies 
with pre-term pre-eclampsia with severe features. As shown in 
Figure  5D, we did not observe significant differences between 
uncomplicated pregnancies and pregnancies with pre-eclampsia 
at term. However, despite large variations among samples, we 
detected a statistically significant difference in GPNMB expres-
sion between placentas of term pre-eclampsia and pre-term 
pre-eclampsia with severe feature, with the latter group showing 
reduced GPNMB expression.
FigUre 6 | The inhibitory receptor programmed cell death 1 (PD1) is highly expressed among placental T cells. (a) Expression of PD1 and ILT2 (CD85J) on 
placental CD4 and CD8 T cells. Gate was applied on CD19−CD3+ T cells. Four representative donors out of 16 are depicted. (B,c) Percentages of PD1+  
(B) and ILT2+ (c) CD4 or CD8 T cells in different donors (n = 16). ****p < 0.0001. Significance was calculated by Student’s t-tests.
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The PD1/PD ligand 1 (PDl1) Pathway is 
highly represented in normal Term 
Placenta
As PD1 ligands, specifically CD274, had higher expression on 
HLA-DRhigh myeloid cells, we hypothesized that this pathway 
could contribute to maintenance of tolerance during pregnancy. 
We therefore investigated expression of PD1 on T cells in nor-
mal term placenta. Interestingly, very high percentages of CD4 
(41.5–70%) and CD8 (32.3–79.6%) T cells expressed high levels of 
PD1 ex vivo in all the donors tested (Figures 6A,B). To determine 
whether placenta T cells exclusively express PD1 or whether they 
also express other inhibitory receptors, we investigated expres-
sion of ILT2 (CD85J and LILRB1) which binds HLA-G present on 
syncytium-trophoblast (29) and also on our myeloid cell subsets 
(not shown). We found that a few CD4 (1.7–21%) and some CD8 
(9.4–41.8%) expressed ILT2 (Figure 6C). However, expression of 
ILT2 was more variable among donors and never as prominent 
as PD1 expression.
This findings support the idea that the PD1/PDL1 axis might 
limit T-cell expansion driven by fetal alloantigen and may play a 
key role in human pregnancy and in establishing tolerance to the 
fetal allotransplant.
DiscUssiOn
In this study, we identified two subsets of CD14+ myeloid cells 
that differ in terms of functional responses to TLR stimulation 
and cell surface receptors and have a very distinct transcriptional 
profile. A seminal study previously described two unique human 
decidual populations based on differential expression of CD11c 
(30). However, few of the genes identified in our study were also 
differentially expressed in those two subsets.
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We find that our HLA-DRhigh cells produce more IL-10 and 
express higher level of EBI3, a subunit of IL-27 and IL-35, two 
members of the IL-12 family of cytokines. Notably, IL-27 and 
IL-35 have both immunosuppressive and anti-inflammatory 
properties, though by different mechanisms (31–34). IL-27 is 
involved in induction of peripheral Foxp3− Tregulatory 1 (Tr1) 
T cells, which are immunosupressive through the production of 
IL-10 (35–38). IL-35 instead is produced by conventional Foxp3+ 
Treg, which directly suppresses T-cell proliferation and differen-
tiation (39). B cells can also produce IL-35 (40), which in turn 
induces other B cells to produce IL-10 (41, 42). From our data, 
it is not clear whether HLA-DRhigh cells produce IL-27 or IL-35. 
However, when we looked in placental BP tissue for induced Tr1, 
based on expression of CD49b and LAG-3, as previously reported 
(43), we did not detect any substantial population of Tr1 among 
CD4 T cells. Furthermore, we did not find a significant popula-
tion of CD4 T cells producing IL-10, when CD4 were maximally 
stimulated with PMA and Ionomycin (data not shown).
Interestingly, our HLA-DRhigh myeloid cells expressed many 
factors of the complement cascade, as well as APOE and APOC2. 
It is well established that during pregnancy there is a systemic 
activation of the complement systems (44) and hyperlipopro-
teinemia. Increase in Apo-CII in serum is documented in late 
pregnancy (45). Our data now raise the intriguing possibility 
that placenta-associated myeloid cells may be a direct source of 
complement factors and apolipropoteins, whose levels increase in 
serum during pregnancy.
HLA-DRhigh myeloid cells express PD1 ligands and other 
inhibitory receptors, such as ILTs (46). Importantly, PD1 is highly 
expressed on a large fraction of CD8 and CD4 cells on all donors 
tested, suggesting that the PD1/PD1 ligands’ axis is positioned to 
be an important player in establishing and maintaining tolerance 
in human pregnancy, similar to the role that PD1/PD1 ligands 
play in tumors (47, 48). Accordingly, blockade of PDL1 increases 
rejection of allogeneic concepti in mouse models (49). High 
expression of ILT2 and ILT4 on HLA-DRhigh cells may also favor 
CD8 T cells with a Type-2 cytokine-secreting phenotype (50). In 
addition, because ILT2 and ILT4 binds to MHC class I, they might 
bind class I molecules in cis and sequester them from binding to 
TCR for antigen presentation to CD8 T cells (51).
We show that HLA-DRhigh cells produce GPNMB, a soluble 
mediator expressed by highly aggressive tumors and now a 
putative target for cancer therapy (28). GPNMB expression on 
HLA-DRhigh cells is likely driven by expression of the TF MITF, 
given the correlating expression pattern (22, 23). Although we did 
not observe any specific effects of soluble GPNMB in inhibiting 
proliferation of anti-CD3 stimulated T cells (data not shown), we 
cannot exclude that GPNMB has indirect immunosuppressive 
function on other cell types that in turn regulate T-cell prolifera-
tion and differentiation. We did observe that GPNMB expression 
was significantly lower in pre-term pre-eclampsia with severe fea-
ture. It has previously been shown that overexpression of GPNMB 
results in lower levels of pro-inflammatory cytokines, including 
IL-6 and IL-12 (52), which are elevated in pre-eclampsia (53). 
In other pathological conditions, such as in acute kidney injury, 
GPNMB functions as a negative regulator of inflammation by 
promoting IL-10 and TGF-β secretion (54). Therefore, a decrease 
in GPNMB expression in pre-eclampsia with severe features may 
represent a sign of worse disease. Alternatively, GPNMB may be 
upregulated with pregnancy progression. In the future differenti-
ating between these two hypotheses will be important, as GPNMB 
levels in serum of pregnant women may be used as a potential 
biomarker to monitor the course and severity of pre-eclampsia.
Despite the fact that our HLA-DRhigh subset bears some fea-
tures of TGF-β imprinting, such as higher CD9 expression, we 
did not observe a specific niche within the decidual tissue or the 
villi in which MITF+CD163+CD14+ were preferentially located. 
On the contrary, these cells were interspersed with MITF− 
CD163+CD14+ cells. This evidence may suggest that either TGF-β 
signaling differs between the two subsets or that one subset 
may convert to the other under yet unknown circumstances. 
Additional studies in animal models will be necessary to dissect 
these hypotheses.
In contrast to HLA-DRhigh cells, HLA-DRlow cells seem pre-
pared to mount anti-bacterial response based on their expres-
sion of pro-inflammatory factors such as many S100 proteins, 
IL-6, IL-1β, NOD2, and NLRP3. Collectively these factors are 
well-known drivers of acute inflammation following recogni-
tion of bacterial components in part via the inflammasome. This 
idea is also supported by greater expression of several endocytic 
receptors by HLA-DRlow cells, such as the C-type lectins DCIR, 
MCL, and MICL, which may recognize sugar moieties on 
pathogens. In addition, these cells express IgA receptors, such 
as CD89 and ASGR2, that may bind IgA opsonized bacteria at 
the mucosal surfaces. Finally, greater expression of S100A12 
by HLA-DRlow cells, confirmed by RT-PCR, supports an anti-
microbial role as this protein has large spectrum antibacterial/
antifungal activity due to its zinc binding properties (24, 55).
More in depth analysis and animal models will be required to 
further dissect the function of the two myeloid subsets identified 
in our study. Nevertheless, our data clearly indicate the existence 
of at least two subsets of myeloid cells (monocytes/macrophages) 
in the BP of human normal term placentas, which may differ in 
their functional properties. One subset seems to exhibit a tolero-
genic signature and to utilize immunosuppressive pathways that 
are often hijacked by tumors to avoid immune surveillance. The 
second subset seems to have more pro-inflammatory and defense 
properties and might be involved in protecting the fetus from 
exogenous pathogens. Single-cell RNA-seq experiments will also 
be required to verify whether diverse cell types are hidden in each 
subset, as recently shown for peripheral blood monocytes (56), or 
whether they represent homogenous populations with a unique 
transcriptional signature.
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